Page 16 - T Cell News Today

Cutting-edge cancer treatments like immunotherapy are offering new hope for patients, often in combination with more common approaches such as chemotherapy. But determining the best treatment combination isn't always straightforward.

MyJournals.org - Science - IJMS, Vol. 24, Pages 8525: Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose (International Journal of Molecular Sciences)

A recent study discusses alterations in the human metabolic fingerprint associated with the keto diet.

The new technique, which was just published in Cell Reports, can reduce T cell fatigue even in cancers that are resistant to clinically approved immunotherapies. It can also keep T cells from becoming exhausted.  

Nearly 90 percent of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.

Cancer immunotherapy has transformed the treatment of many types of cancer. Yet, for reasons that remain poorly understood, not all patients get the same benefit from these powerful therapies.

In an 11-year study, researchers at the National Institutes of Health have further characterized idiopathic CD4 lymphocytopenia (ICL), a rare immune deficiency that leaves people vulnerable to infectious diseases, autoimmune diseases and cancers.

Gut bacteria that break down a sugar called fucose could be dampening our immune response to the COVID-19 mRNA vaccine, according to a study led by researchers from the Okinawa Institute of Science and Technology.

The findings illustrate the important impact that the trillions of bacteria in our gut -- collectively called our 'gut microbiome' -- have on our immune health and add a missing piece to the puzzle of why vaccination varies in effectiveness from person to person

MyJournals.org - Science - IJMS, Vol. 24, Pages 7626: Mutated Flt3Lg Provides Reduced Flt3 Recycling Compared to Wild-Type Flt3Lg and Retains the Specificity of Flt3Lg-Based CAR T-Cell Targeting in AML Models (International Journal of Molecular Sciences)